Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 264

1.

Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery.

Yang KL, Yang SH, Liang WY, Kuo YJ, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chang SC, Chu LS, Wang LW.

Radiat Oncol. 2013 Mar 1;8:43. doi: 10.1186/1748-717X-8-43.

2.

Assessment of the value of carcinoembryonic antigen reduction ratio as a prognosis factor in rectal cancer.

Huang CS, Lin JK, Wang LW, Liang WY, Lin CC, Lan YT, Wang HS, Yang SH, Jiang JK, Chen WS, Lin TC, Chang SC.

Am J Surg. 2014 Jul;208(1):99-105. doi: 10.1016/j.amjsurg.2013.08.054. Epub 2014 Jan 16.

PMID:
24524862
3.

Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection.

Kim CW, Yu CS, Yang SS, Kim KH, Yoon YS, Yoon SN, Lim SB, Kim JC.

Ann Surg Oncol. 2011 Nov;18(12):3271-7. doi: 10.1245/s10434-011-1740-1. Epub 2011 May 3.

PMID:
21537868
4.

Carcinoembryonic antigen as a predictor of pathologic response and a prognostic factor in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and surgery.

Park JW, Lim SB, Kim DY, Jung KH, Hong YS, Chang HJ, Choi HS, Jeong SY.

Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):810-7. doi: 10.1016/j.ijrobp.2008.08.057. Epub 2008 Dec 26.

PMID:
19101093
5.

Reappraisal of pretreatment carcinoembryonic antigen in patients with rectal cancer receiving preoperative chemoradiotherapy.

Yeo SG, Kim DY, Chang HJ, Park JW, Oh JH, Kim BC, Baek JY, Kim SY, Kim TH.

Tumori. 2013 Jan-Feb;99(1):93-9. doi: 10.1700/1248.13795.

PMID:
23549007
6.

Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer.

Park YA, Sohn SK, Seong J, Baik SH, Lee KY, Kim NK, Cho CW.

J Surg Oncol. 2006 Feb 1;93(2):145-50.

PMID:
16425302
7.

CEA - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer.

Wallin U, Rothenberger D, Lowry A, Luepker R, Mellgren A.

Dis Colon Rectum. 2013 Jul;56(7):859-68. doi: 10.1097/DCR.0b013e31828e5a72.

PMID:
23739192
8.

C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery.

Toiyama Y, Inoue Y, Saigusa S, Kawamura M, Kawamoto A, Okugawa Y, Hiro J, Tanaka K, Mohri Y, Kusunoki M.

Anticancer Res. 2013 Nov;33(11):5065-74.

PMID:
24222151
10.

The role of fibrinogen as a predictor in preoperative chemoradiation for rectal cancer.

Lee JH, Hyun JH, Kim DY, Yoo BC, Park JW, Kim SY, Chang HJ, Kim BC, Kim TH, Oh JH, Sohn DK.

Ann Surg Oncol. 2015 Jan;22(1):209-15. doi: 10.1245/s10434-014-3962-5. Epub 2014 Nov 11.

PMID:
25384698
11.

Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.

Shanmugan S, Arrangoiz R, Nitzkorski JR, Yu JQ, Li T, Cooper H, Konski A, Farma JM, Sigurdson ER.

Ann Surg Oncol. 2012 Jul;19(7):2178-85. doi: 10.1245/s10434-012-2248-z. Epub 2012 Mar 7.

PMID:
22395978
13.

Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer.

Tural D, Ozturk M, Selcukbiricik F, Yildiz O, Elicin O, Turna H, Guney S, Ozguroglu M.

J BUON. 2013 Apr-Jun;18(2):385-90.

PMID:
23818350
15.

Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy.

Agostini M, Pucciarelli S, Enzo MV, Del Bianco P, Briarava M, Bedin C, Maretto I, Friso ML, Lonardi S, Mescoli C, Toppan P, Urso E, Nitti D.

Ann Surg Oncol. 2011 Sep;18(9):2461-8. doi: 10.1245/s10434-011-1638-y. Epub 2011 Mar 17.

PMID:
21416156
16.

Can serum dynamics of carcinoembryonic antigen level during neoadjuvant chemoradiotherapy in rectal cancer predict tumor response and recurrence? A multi-institutional retrospective study.

Chung MJ, Nam TK, Jeong JU, Kim SH, Kim K, Jang HS, Jeong BK, Lee JH.

Int J Colorectal Dis. 2016 Sep;31(9):1595-601. doi: 10.1007/s00384-016-2629-z. Epub 2016 Jul 28.

PMID:
27464635
17.

Chemoradiation-induced changes in serum CEA and plasma TIMP-1 in patients with locally advanced rectal cancer.

Aldulaymi B, Christensen IJ, Sölétormos G, Jess P, Nielsen SE, Laurberg S, Brünner N, Nielsen HJ.

Anticancer Res. 2010 Nov;30(11):4755-9.

PMID:
21115936
18.

Carcinoembryonic antigen has prognostic value for tumor downstaging and recurrence in rectal cancer after preoperative chemoradiotherapy and curative surgery: A multi-institutional and case-matched control study of KROG 14-12.

Lee JH, Kim DY, Kim SH, Cho HM, Shim BY, Kim TH, Kim SY, Baek JY, Oh JH, Nam TK, Yoon MS, Jeong JU, Kim K, Chie EK, Jang HS, Kim JS, Kim JH, Jeong BK.

Radiother Oncol. 2015 Aug;116(2):202-8. doi: 10.1016/j.radonc.2015.07.049. Epub 2015 Aug 21.

PMID:
26303015
19.

Predictors of sensitivity to preoperative chemoradiotherapy of rectal adenocarcinoma.

Yan H, Wang R, Zhu K, Zhao W, Jiang S, Feng R, Xu X, Meng X, Sun H, Zhang H, Mu D, Xu Z.

Tumori. 2011 Nov-Dec;97(6):717-23. doi: 10.1700/1018.11087.

20.

Blood biomarkers are helpful in the prediction of response to chemoradiation in rectal cancer: a prospective, hypothesis driven study on patients with locally advanced rectal cancer.

Buijsen J, van Stiphout RG, Menheere PP, Lammering G, Lambin P.

Radiother Oncol. 2014 May;111(2):237-42. doi: 10.1016/j.radonc.2014.03.006. Epub 2014 Apr 16.

PMID:
24746569

Supplemental Content

Support Center